Recurrent Melanoma Withdrawn Phase 2 Trials for Temsirolimus (DB06287)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01851408Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable MelanomaTreatment